{"nctId":"NCT02476617","briefTitle":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","startDateStruct":{"date":"2015-06"},"conditions":["Chronic Hepatitis C","Hepatitis C (HCV)","Hepatitis C Genotype 1a"],"count":25,"armGroups":[{"label":"Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: dasabuvir","Drug: ribavirin"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir","otherNames":["ABT-267/ABT-450/ritonavir"]},{"name":"dasabuvir","otherNames":["ABT-333"]},{"name":"ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Screening laboratory result indicating hepatitis C viral (HCV) genotype (GT) 1a infection.\n2. Chronic HCV infection.\n3. Participants must be non-cirrhotic.\n4. Participants must be treatment-na√Øve or have documentation that they were adherent to prior pegIFN/RBV combination therapy and meet the criteria of prior pegylated-interferon (pegIFN)/ribavirin (RBV) treatment failure.\n5. Participants must meet specific human leukocyte antigen (HLA) allele requirements.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding.\n2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) positive immunoassay.\n3. Clinically significant abnormalities or co-morbidities, other than HCV infection, that make the subject unsuitable for this study or treatment.\n4. Current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-HCV agents other than pegIFN or RBV (including previous exposure to paritaprevir, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.\n5. History of solid organ transplant.\n6. Screening laboratory analysis that shows abnormal results.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12","description":"The changes from week 0 to post-treatment (PT) week 12 in key ISG expression in PBMCs for participants achieving sustained virologic response 12 weeks PT (SVR12) where SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\\<LLOQ) 12 weeks after the last dose of study drug. For each key ISG, fold change was defined as the ratio of the difference between PT Week 12 and baseline expressions over the baseline expression.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.464","spread":"0.6143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.148","spread":"0.7458"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.611","spread":"0.3090"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.399","spread":"0.3013"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.462","spread":"0.4624"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.168","spread":"0.5168"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.016","spread":"0.5696"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.543","spread":"0.3350"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.467","spread":"0.2569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.301","spread":"0.3430"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.552","spread":"0.2816"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.440","spread":"0.4441"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.358","spread":"0.2827"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.171","spread":"0.4273"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":"1.4668"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.255","spread":"0.3688"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.205","spread":"0.2809"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.321","spread":"0.3213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.5282"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.130","spread":"0.6497"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"0.6307"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.051","spread":"0.5762"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.516","spread":"1.4653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.361","spread":"0.3753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.199","spread":"0.7031"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.205","spread":"0.4306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.228","spread":"0.7298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.046","spread":"0.3008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.212","spread":"0.2314"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.083","spread":"0.7491"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.101","spread":"0.5739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.200","spread":"1.5071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.638","spread":"1.7396"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.556","spread":"2.7478"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.085","spread":"2.7539"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.308","spread":"0.5236"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"1.2134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.388","spread":"1.2231"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.869","spread":"1.5730"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.317","spread":"0.2521"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.288","spread":"0.4421"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.5267"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.350","spread":"0.7909"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.232","spread":"0.5124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.074","spread":"0.3294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.023","spread":"0.6428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.554","spread":"0.4068"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.464","spread":"0.3010"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.365","spread":"0.4118"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.291","spread":"0.2085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.066","spread":"0.3696"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.158","spread":"0.7905"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.423","spread":"0.3313"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.202","spread":"0.5037"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.167","spread":"0.4427"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.202","spread":"0.8216"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.078","spread":"0.2695"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.311","spread":"1.0487"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.156","spread":"1.0071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.072","spread":"0.2983"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.185","spread":"0.4048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.005","spread":"0.7458"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.101","spread":"0.6188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":"0.2404"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.249","spread":"0.8288"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.017","spread":"0.3577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.233","spread":"0.6984"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.011","spread":"0.1956"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.395","spread":"0.9973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.406","spread":"0.3202"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.9149"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.313","spread":"3.5778"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.025","spread":"1.1773"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.288","spread":"0.3092"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":25},"commonTop":["FATIGUE","NAUSEA","HEADACHE","INSOMNIA","DIARRHOEA"]}}}